biologics

July Clinical ConsiderationsIn this month's Clinical Considerations, we take a look at biologics and treatments for seborrheic keratoses.
Prescribing barriersDermatologists who plan to prescribe brodalumab may face a rough road.
FDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosisFDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
Biosimilar familiarity expandsDermatologists and some psoriasis patients might soon grapple with switching from a biologic to a biosimilar.
Biologic class differentiatorsDermatology experts offer insight into differentiating factors among TNF-alpha inhibitors, the IL 12/23 antagonist, IL 17 inhibitors and an oral option that carry considerations for managing certain patients.
A peek at the pipelineThere is tremendous excitement surrounding IL-23 inhibitors for the treatment of psoriasis. Three are currently in the pipeline.
Paradoxical reactions to biologics provide insightParadoxical reactions to biologic treatments can provide clues into related conditions such as granulomatous diseases, genetic polymorphisms and latent infections, says an expert.
Asthma biologic may reduce oral steroid useA new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
New treatments on the horizonEmerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.